At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 564 enrolled
Drug / intervention
SUVN-502 +3 moredrug
Likely dose
Donepezil 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
In Brief
A Phase 2 clinical trial evaluating SUVN-502, Placebo, and 2 other interventions for Alzheimer's Disease. Completed, enrolled 564 participants across 71 sites.
Detailed Summary
This is a phase 2a, proof-of-concept, 26-week, double-blind, multicenter, randomized, parallel group, placebo-controlled study to compare the efficacy and safety of treatment with SUVN-502 to placebo treatment in subjects with moderate Alzheimer's disease receiving stable doses of donepezil HCl and memantine HCl.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartSep 2015
First PostedOct 2015
Primary CompletionNov 2019
Study CompletionNov 2019
TodayJul 2026
First PostedOct 20, 2015
Enrollment StartSep 1, 2015
Primary CompletionNov 5, 2019
Study CompletionNov 7, 2019
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 10.7 years ago
Interventions
SUVN-502drug
Once-daily, tablets, orally
Placebodrug
Once-daily, tablets, orally
Donepezildrug
Donepezil HCl (10 mg, once a day)
Memantinedrug
Memantine HCl (10 mg, twice a day or 28 mg extended-release, once a day).